FDA approves for the activL artificial disc for one-level lumbar use

Aesculap Receives FDA Approval for the activL® Artificial Disc for One-Level Lumbar Use (press release) Intelligent Motion Technology for Total Disc Replacement; activL Is Designed as an Alternative to Spinal Fusion Surgery to Allow Motion at the Treated Level of the Lower Back Aesculap Implant Systems, LLC (Aesculap), a privately held medical device company, announced today that it has received a letter of approval from the U.S. Food and Drug Administration (FDA) allowing the commercial sale of the activL® Artificial Disc, for the treatment of one-level lumbar degenerative disc disease. Chuck...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top